High-throughput drug screening uses inexpensive primary screens to select compounds for more costly follow-up dose-response experiments, which estimate compound potency (pXC50) by determining the concentration required to produce a specified biological effect. However, many promoted compounds fail to yield a reportable potency, even when activity is subsequently confirmed. We investigated whether inexpensive three-point primary-screening data could predict whether a more costly 11-point dose-response experiment would yield a reportable pXC50. Using a dataset of 32,971 compound-assay pairs with three-point primary-screening and 11-point dose-response measurements, we trained random-forest models to predict successful potency quantification. Our model achieved an AUROC of 0.939 +/- 0.002 and generalized to previously unseen chemical scaffolds and assay-mechanism families. We found that primary-screen response features were more predictive of dose-response quantifiability than molecular structure-based features. Successful potency quantification was also strongly associated with primary-screen response amplitude. Across eight chronological test releases, the model retrospectively retained 90% of reportable potencies while selecting only 55.7% of historically promoted compound-assay pairs for follow-up profiling. These findings suggest that predicting potency quantifiability from primary-screening data could improve the efficiency of compound prioritization and reduce unnecessary dose-response experiments.

翻译：暂无翻译